...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: New MD&A posted
6
Dec 17, 2019 06:56AM
2
Dec 17, 2019 08:09AM

 

The results of the BETonMACE study validate the need to continue the clinical development of apabetalone in patients with high-risk CVD, an area of critical unmet need. Novel medications capable of reducing this residual risk are urgently needed; therefore, apabetalone represents a novel and potentially more effective approach to this clinical issue. Based on the results of the BETonMACE study, breakthrough therapy status filings for both the FDA and EMA is underway. Additionally, partnership discussions based on the results from the BETonMACE study, including the synergistic finding with new classes of anti-diabetic therapies, the pronounced effect on patients with CKD stages 3 or worse, the improvement in cognition in cognitively impaired patients and the observed effect on CHF are ongoing. Appropriate IP filings are ongoing.   

5
Dec 17, 2019 08:26AM
1
Dec 17, 2019 09:14AM
6
Dec 17, 2019 10:11AM
4
Dec 17, 2019 10:19AM
3
Dec 17, 2019 10:31AM
3
Dec 17, 2019 10:41AM
5
Dec 17, 2019 11:02AM
2
Dec 17, 2019 11:08AM
1
Dec 17, 2019 11:09AM
1
Dec 17, 2019 11:14AM
4
Dec 17, 2019 11:57AM
4
Dec 17, 2019 12:37PM
4
Dec 17, 2019 12:46PM
4
Dec 17, 2019 10:41PM
7
Dec 18, 2019 07:01AM
4
Dec 18, 2019 01:15PM
5
Dec 18, 2019 01:23PM
3
Dec 18, 2019 01:49PM
5
Dec 18, 2019 03:18PM
1
Dec 18, 2019 03:43PM
2
Dec 18, 2019 03:55PM
1
BKC
Dec 18, 2019 04:00PM
5
Dec 18, 2019 05:06PM
2
Dec 18, 2019 07:43PM
4
Dec 18, 2019 08:09PM
2
Dec 18, 2019 08:23PM
3
Dec 18, 2019 08:29PM
1
Dec 18, 2019 09:55PM
1
Dec 18, 2019 10:35PM
3
Dec 19, 2019 02:08AM
4
Dec 19, 2019 02:34AM
1
Dec 19, 2019 07:17AM
1
Dec 19, 2019 08:03AM
2
Dec 19, 2019 08:27AM
2
Dec 19, 2019 08:37AM
2
Dec 19, 2019 08:47AM
1
Dec 19, 2019 08:56AM
2
Dec 19, 2019 08:58AM
1
Dec 19, 2019 09:25AM

Dec 19, 2019 11:34AM
Share
New Message
Please login to post a reply